CatalystAlertBeta

Briefing Calendar News IPOs Opportunities Companies Compare Analytics Watchlist Learn

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar with AI-powered predictions. Track FDA decisions, PDUFA dates, clinical trial results, and Phase 3 readouts. Real-time alerts for biotech investors.

Quick Links

This Week's Catalysts
Full Calendar
Catalyst Types
Search Companies
Short Interest
Smart Money
Biotech Glossary

Legal

About
ML Track Record
Privacy
Terms
Cookies

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

Follow Us

⚠️ Important Legal Disclaimer

Not Financial Advice: CatalystAlert is an informational platform only. We are NOT a registered investment advisor, broker, or dealer. The information provided on this website does not constitute investment advice, financial advice, trading advice, or any other sort of advice, and you should not treat any of the website's content as such.

No Guarantees: All predictions, probability scores, and analyses are based on historical data and machine learning models. Past performance does NOT guarantee future results. Biotech investing is extremely high-risk and you may lose your entire investment.

Data Accuracy: While we strive for accuracy, data may be incomplete, delayed, or contain errors. We aggregate data from third-party sources (FDA, SEC, ClinicalTrials.gov) and are not responsible for their accuracy. Always verify information with official sources before making any decisions.

Your Responsibility: You are solely responsible for your investment decisions. Consult a qualified financial advisor before investing. CatalystAlert and its operators accept no liability for any losses incurred from using this platform.

© 2026 CatalystAlert. All rights reserved.

Data may be delayed or incomplete. Use at your own risk.

Home Calendar News Learn Account

difelikefalin 2.0 mg - Phase 2 | CARA Pipeline | CatalystAlert

difelikefalin 2.0 mg

Phase 2

Cara Therapeutics, Inc. (CARA)

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

8 competitors in Pruritus

VYNE5mg Serlopitant Tablets

VYNEPlacebo Tablets

VYNESerlopitant High Dose

VYNE5 mg Serlopitant Tablets

VYNEMatching Placebo Tablets

View Full Landscape

Drug Information

Target Indication

Pruritus

Clinical Trial

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA4/25/2022

Kapruvia

Kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.1).

Drug Science

Mechanism of action & safety profile

Developer

CARA

Cara Therapeutics, Inc.

Biotechnology•North America•NASDAQ

Related Pipeline

CR845 IV 1 mcg/kgPhase 3

Post Abdominal Surgery Pain

CR845 1 mcg/kgPhase 3

Uremic Pruritus

Postoperative Pain

CR845 0.5 mcg/kgPhase 3

Uremic Pruritus

difelikefalin 0.25 mgPhase 2

Pruritus

View full pipeline